Search Results

September 2022 Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model antibody atezolizumab and nab-paclitaxel has shown clinical activity in advanced TNBC with PD-L1-positive tumor-infiltrating As tumor-associated macrophages (TAMs) serve as major contributors to the immuno-suppressive tumor microenvironment We show that through proper calibration, the model captures the macrophage heterogeneity in the tumor

and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors

Here, using colorectal cancer (CRC) as a model, we explored the gene expression of a panel of GPCRs in tumor live-imaging modalities, and displayed high efficiency when used to label complex 3D cellular systems such as tumor A2BAR as a potential pharmacological tool in CRC, using selective antagonists, finding a reduction in tumor

Our guests were Maria Waldhoer , Tudor I. Oprea , Thomas Sakmar , Aurelien Rizk & Yaroslav Nikolaev .

Increasing evidence reveals the heightened expression of olfactory receptors in tumorous tissues and Olfactory receptors have demonstrated influence over tumor cell proliferation and metastasis, establishing a close relationship with tumor initiation and progression. The potential for precise tumor diagnosis and targeted therapy through therapeutic targeting of olfactory cell proliferation , Tumor development , Tumor metastasis .

GPCRs in Oncology and Immunology Exploiting frequent and specific expression of PRL3 in pediatric solid tumors Published date September 21, 2023 Abstract "Phosphatase of regenerating liver 3 (PRL3) is a specific tumor However, its physiological expression in pediatric embryonal and mesenchymal tumors and its association Among 64 pediatric tumors, PRL3 was most frequently expressed in neuroblastoma (100%), rhabdomyosarcoma PRL3 was expressed in 75% of relapsed tumors and associated with shorter median event-free survival.